Kimal I Rajapakshe
Overview
Explore the profile of Kimal I Rajapakshe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makino Y, Rajapakshe K, Chellakkan Selvanesan B, Okumura T, Date K, Dutta P, et al.
Gut
. 2024 Sep;
74(1):75-88.
PMID: 39277181
Background: Oncogenic 'hotspot' mutations of and are two major driver alterations in intraductal papillary mucinous neoplasms (IPMNs), which are precursors to pancreatic ductal adenocarcinoma. We previously reported that pancreas-specific and...
2.
Dilly J, Hoffman M, Abbassi L, Li Z, Paradiso F, Parent B, et al.
Cancer Discov
. 2024 Jul;
14(11):2135-2161.
PMID: 38975874
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and...
3.
Bahrambeigi V, Lee J, Branchi V, Rajapakshe K, Xu Z, Kui N, et al.
Cancer Res
. 2024 Mar;
84(10):1719-1732.
PMID: 38451249
Significance: The development of an approach to interrogate molecular subtypes, cancer-associated pathways, and differentially expressed genes through RNA sequencing of plasma extracellular vesicles lays the foundation for liquid biopsy-based longitudinal...
4.
Semaan A, Bernard V, Wong J, Makino Y, Swartzlander D, Rajapakshe K, et al.
Cancer Res Commun
. 2023 Sep;
3(10):2062-2073.
PMID: 37721516
Significance: Integrated molecular analysis of genomic and transcriptomic alterations in the multistep progression of IPMNs, which are bona fide precursors of pancreatic cancer, identifies features associated with progression of low-risk...
5.
Sans M, Chen Y, Thege F, Dou R, Min J, Yip-Schneider M, et al.
bioRxiv
. 2023 Aug;
PMID: 37645752
Background: The development of diverse spatial profiling technologies has provided an unprecedented insight into molecular mechanisms driving cancer pathogenesis. Here, we conducted the first integrated cross-species assessment of spatial transcriptomics...
6.
Sans M, Makino Y, Min J, Rajapakshe K, Yip-Schneider M, Schmidt C, et al.
Cancer Discov
. 2023 Jun;
13(8):1844-1861.
PMID: 37285225
Significance: Identification of the molecular features driving IPMN development and differentiation is critical to prevent cancer progression and enhance risk stratification. We used spatial profiling to characterize the epithelium and...
7.
Li C, Rajapakshe K, Maitra A
Pancreatology
. 2022 Aug;
22(7):965-972.
PMID: 36008214
Background: Recent advances on pancreatic cancer molecular classifications have identified several subtypes with distinct characteristics, treatment response, and prognosis. We aim to identify the consensus gene signature that could predict...
8.
Wormann S, Zhang A, Thege F, Cowan R, Rupani D, Wang R, et al.
Nat Cancer
. 2022 Feb;
2(12):1338-1356.
PMID: 35121902
Despite efforts in understanding its underlying mechanisms, the etiology of chromosomal instability (CIN) remains unclear for many tumor types. Here, we identify CIN initiation as a previously undescribed function for...
9.
Lee J, Bernard V, Semaan A, Monberg M, Huang J, Stephens B, et al.
Clin Cancer Res
. 2021 Aug;
27(21):5912-5921.
PMID: 34426439
Purpose: Precision medicine approaches in pancreatic ductal adenocarcinoma (PDAC) are imperative for improving disease outcomes. With molecular subtypes of PDAC gaining relevance in the context of therapeutic stratification, the ability...
10.
Hamilton M, Rajapakshe K, Bader D, Cerne J, Smith E, Coarfa C, et al.
Neoplasia
. 2016 Jun;
18(6):356-70.
PMID: 27292025
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of...